文献

J-GLOBAL ID：202002277767504426   整理番号：20A1174643

‘ステルスの企業革新:治療薬開発の新たな脅威【JST・京大機械翻訳】

‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

著者 (24件)： Mastellos Dimitrios C. (National Center for Scientific Research ‘Demokritos’, Aghia Paraskevi, Athens, Greece) ,  Blom Anna M. (Department of Translational Medicine, Lund University, Lund, Sweden) ,  Connolly E. Sander (Department of Neurological Surgery, Columbia University, New York, NY, USA) ,  Daha Mohamed R. (Leiden University Medical Center, Leiden, Netherlands) ,  Geisbrecht Brian V. (Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA) ,  Ghebrehiwet Berhane (Department of Medicine, Division of Rheumatology, Allergy and Immunology, Stony Brook University, New York, NY, USA) ,  Gros Piet (Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, Netherlands) ,  Hajishengallis George (Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA) ,  Holers V. Michael (Division of Rheumatology, Departments of Medicine and Immunology, University of Colorado School of Medicine, Denver, CO, USA) ,  Huber-Lang Markus (Institute of Clinical and Experimental Trauma immunology, University of Ulm, Ulm, Germany) ,  Kinoshita Taroh (Research Institute for Microbial Diseases Osaka University and Laboratory of Immunoglycobiology, Immunology Frontier Research Center, Osaka University, Osaka, Japan) ,  Mollnes Tom E. (Department of Immunology, Oslo University Hospital, and University of Oslo, Oslo, Norway) ,  Mollnes Tom E. (Research Laboratory, Nordland Hospital, Bodo, and K.G. Jebsen TREC, University of Tromso, Tromso, Norway) ,  Mollnes Tom E. (Centre of Molecular Inflammatory Research, NTNU, Trondheim, Norway) ,  Montgomery Robert A. (Department of Surgery, NYU Langone Transplant Institute, New York, NY, USA) ,  Morgan B. Paul (Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, UK) ,  Nilsson Bo (Division of Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden) ,  Pio Ruben (Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, IDISNA, CIBERONC, Pamplona, Spain) ,  Ricklin Daniel (Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland) ,  Risitano Antonio M. (Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy) ,  Taylor Ronald P. (Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA) ,  Mantovani Alberto (Istituto Clinico Humanitas, Humanitas University, Milan, Italy) ,  Ioannidis John P. A. (Meta-Research Innovation Center at Stanford, and Departments of Medicine, of Health Research and Policy, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, CA, USA) ,  Lambris John D. (Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA)
資料名： Nature Immunology  (Nature Immunology)
巻： 20  号： 11  ページ： 1409-1413  発行年： 2019年 
JST資料番号： W1330A  ISSN： 1529-2908  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 潜在的に大きな臨床的影響の治療的革新は,科学的なピアレビュープロセスを通して,研究責任,データ透明性および検証のオーバーラップ値を包含するべきである。Copyright Springer Nature America, Inc. 2019 Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *製品開発 ,  *改良 ,  *審査 ,  *性質 ,  創薬
準シソーラス用語： 組織革新 ,  オーバラップ , 【Automatic Indexing@JST】

分類 (1件)： 免疫反応一般  (ED03010T)

タイトルに関連する用語 (3件)： 企業革新 ,  治療薬開発 ,  脅威